NASDAQ Companies

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming […]

FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing […]

WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing […]

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company […]

Appointment effective February 12 following Nadim Yared’s retirement Hykes currently serves as Augmedics’ President and CEO, and has served on […]

23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells ‘1473 has dual mechanisms of […]

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving […]

NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the […]

TROY, Michigan, Jan. 31, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of […]

Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modalities Biogen committed […]